Detailed narrative
Leasing Trends and Market Dynamics
Leasing volume for Q2 FY26 was strong at 1,039,000 square feet, a 60% increase over the prior quarter. New leasing, including development/redevelopment projects and vacant space, totaled nearly 400,000 square feet. The company observed a significant increase in demand from the life science product/service and device sector (almost 40% of leasing volume) and the advanced technology sector (almost 30%). Public biotech leasing increased to 5.8% from 0% last quarter, though still below its 21% representation in the tenant base. The company is seeing an increase in tenants in the 20,000 to 100,000 square foot size range, which had been lagging.
Capital Recycling and Disposition Program
Alexandria is on track to meet its $2.9 billion disposition target for 2026, with $1.3 billion (46%) completed or pending, and another $1.1 billion (38%) in process. The weighted average projected completion date for the program is September. The disposition mix is refined to 15-35% land, 10-20% noncore assets, and 50-70% sales of partial interest and other capital. The company recognized $222.5 million in real estate impairments during the quarter, primarily related to land and lab conversion opportunities, including a land parcel in Northern San Diego and an office building in Toronto.
Development Pipeline and Strategic Evaluation
The company has 1.4 million square feet of development and redevelopment projects under construction, 71% leased, expected to stabilize through 2028. An additional 1.4 million square feet across five projects are under evaluation for business and financial strategy. The overall pipeline has shrunk by 20% since the beginning of the year. For projects like 311 Arsenal Street, 40 Sylvan Road, and 3,000 Minuteman Road, the company is exploring advanced technology leases, which could reduce capital needs and generate near-term revenue, potentially shifting these spaces into the operating pool.
Balance Sheet and Liquidity
Alexandria maintains a strong balance sheet with corporate credit ratings in the top 20% of S&P 500 REITs. Liquidity stands at $3.6 billion as of Q2 FY26. The $5 billion unsecured senior line of credit was extended to 2032. The company has the longest average remaining debt term maturity among S&P 500 REITs at 9.7 years. Leverage (Net Debt to Annualized Adjusted EBITDA) was 7x in Q2 FY26, with a target of 5.6x to 6.2x by Q4 FY26 and mid-5x in the medium term.
Occupancy and Same-Property NOI Performance
Occupancy at the end of Q2 FY26 was 86.9%, an 80 basis point decrease from the prior quarter, primarily due to previously disclosed lease separations. However, 1.4 million square feet of leased space is expected to commence by November 2026, generating $69 million in annual rental revenue. Same-property net operating income was down 10.6% (GAAP) and 8.6% (cash) for Q2 FY26, an improvement from the prior quarter's -1.3% and -3.1% cash basis. Stronger same-property performance is anticipated in H2 FY26, potentially benefiting from the removal of vacant assets designated for sale.
Life Science Industry Outlook and Regulatory Environment
The life science industry continues to be fueled by strong innovation and a solid financing environment, with M&A activity being very strong. However, the regulatory side remains a concern, described as 'a bit of a mess,' despite 23 product approvals year-to-date. China remains a 'big negative overhang.' The company is closely watching interest rates and the impact of IRA implementations. Management also expressed concerns about the potential impact of 'Medicare for all' proposals.